Drug selection and timing of initiation of treatment in early Parkinson's disease
Identifieur interne : 000205 ( Main/Corpus ); précédent : 000204; suivant : 000206Drug selection and timing of initiation of treatment in early Parkinson's disease
Auteurs : Anthony H. V. Schapira ; C. Warren OlanowSource :
- Annals of Neurology [ 0364-5134 ] ; 2008-12.
Abstract
There is increasing evidence to challenge the traditional view that the initiation of drug treatment in Parkinson's disease (PD) should be delayed until the patient has significant disability such as to affect work or social function. Firstly, to delay treatment sentences the patient to protracted impairment of quality of life that could be improved by therapy. Secondly, there is evidence to support the notion that earlier rather than later initiation of treatment leads to better long term motor benefit. The selection of which drug to begin must be tailored to the patient's individual characteristics and circumstances. Monoamine oxidase B inhibitors result in a mild improvement in motor function compared to dopamine agonists or levodopa. They are well tolerated, easy to use once a day drugs and there is evidence that early use of Rasagiline improves motor outcome. Dopamine agonists lead to a substantial improvement in motor function and are, or will shortly be, available as once a day drugs. They are generally well tolerated but can be associated with exacerbating confusion or hallucinations and with behavioral changes. Levodopa is the most potent of the dopaminergic drugs. It is routinely combined with a dopa decarboxylase inhibitor and can also be used with a catecholo‐o‐methyl transferase inhibitor for enhanced absorption. The most important limiting factor for the use of levodopa is the emergence of motor complications. These are related to a number of factors including the dose of levodopa and the duration of its use. Ann Neurol 2008;64 (suppl):S47–S55
Url:
DOI: 10.1002/ana.21460
Links to Exploration step
ISTEX:643A71F9A8ABD53E53147889FF258AAAB8E2EC74Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Drug selection and timing of initiation of treatment in early Parkinson's disease</title><author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H. V." last="Schapira">Anthony H. V. Schapira</name><affiliation><mods:affiliation>University Department of Clinical Neuroscience, Institute of Neurology, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation><mods:affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, NY</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:643A71F9A8ABD53E53147889FF258AAAB8E2EC74</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/ana.21460</idno><idno type="url">https://api.istex.fr/document/643A71F9A8ABD53E53147889FF258AAAB8E2EC74/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000205</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Drug selection and timing of initiation of treatment in early Parkinson's disease</title><author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H. V." last="Schapira">Anthony H. V. Schapira</name><affiliation><mods:affiliation>University Department of Clinical Neuroscience, Institute of Neurology, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation><mods:affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, NY</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-12">2008-12</date><biblScope unit="volume">64</biblScope><biblScope unit="issue">S2</biblScope><biblScope unit="supplement">2</biblScope><biblScope unit="page" from="S47">S47</biblScope><biblScope unit="page" to="S55">S55</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">643A71F9A8ABD53E53147889FF258AAAB8E2EC74</idno><idno type="DOI">10.1002/ana.21460</idno><idno type="ArticleID">ANA21460</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">There is increasing evidence to challenge the traditional view that the initiation of drug treatment in Parkinson's disease (PD) should be delayed until the patient has significant disability such as to affect work or social function. Firstly, to delay treatment sentences the patient to protracted impairment of quality of life that could be improved by therapy. Secondly, there is evidence to support the notion that earlier rather than later initiation of treatment leads to better long term motor benefit. The selection of which drug to begin must be tailored to the patient's individual characteristics and circumstances. Monoamine oxidase B inhibitors result in a mild improvement in motor function compared to dopamine agonists or levodopa. They are well tolerated, easy to use once a day drugs and there is evidence that early use of Rasagiline improves motor outcome. Dopamine agonists lead to a substantial improvement in motor function and are, or will shortly be, available as once a day drugs. They are generally well tolerated but can be associated with exacerbating confusion or hallucinations and with behavioral changes. Levodopa is the most potent of the dopaminergic drugs. It is routinely combined with a dopa decarboxylase inhibitor and can also be used with a catecholo‐o‐methyl transferase inhibitor for enhanced absorption. The most important limiting factor for the use of levodopa is the emergence of motor complications. These are related to a number of factors including the dose of levodopa and the duration of its use. Ann Neurol 2008;64 (suppl):S47–S55</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Anthony H. V. Schapira MD, DSc, FRCP, FMedSci</name><affiliations><json:string>University Department of Clinical Neuroscience, Institute of Neurology, London, United Kingdom</json:string></affiliations></json:item><json:item><name>C. Warren Olanow MD, FRCPC</name><affiliations><json:string>Department of Neurology, Mount Sinai School of Medicine, New York, NY</json:string></affiliations></json:item></author><articleId><json:string>ANA21460</json:string></articleId><language><json:string>eng</json:string></language><abstract>There is increasing evidence to challenge the traditional view that the initiation of drug treatment in Parkinson's disease (PD) should be delayed until the patient has significant disability such as to affect work or social function. Firstly, to delay treatment sentences the patient to protracted impairment of quality of life that could be improved by therapy. Secondly, there is evidence to support the notion that earlier rather than later initiation of treatment leads to better long term motor benefit. The selection of which drug to begin must be tailored to the patient's individual characteristics and circumstances. Monoamine oxidase B inhibitors result in a mild improvement in motor function compared to dopamine agonists or levodopa. They are well tolerated, easy to use once a day drugs and there is evidence that early use of Rasagiline improves motor outcome. Dopamine agonists lead to a substantial improvement in motor function and are, or will shortly be, available as once a day drugs. They are generally well tolerated but can be associated with exacerbating confusion or hallucinations and with behavioral changes. Levodopa is the most potent of the dopaminergic drugs. It is routinely combined with a dopa decarboxylase inhibitor and can also be used with a catecholo‐o‐methyl transferase inhibitor for enhanced absorption. The most important limiting factor for the use of levodopa is the emergence of motor complications. These are related to a number of factors including the dose of levodopa and the duration of its use. Ann Neurol 2008;64 (suppl):S47–S55</abstract><qualityIndicators><score>7.964</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 783 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>1583</abstractCharCount><pdfWordCount>7048</pdfWordCount><pdfCharCount>44742</pdfCharCount><pdfPageCount>9</pdfPageCount><abstractWordCount>247</abstractWordCount></qualityIndicators><title>Drug selection and timing of initiation of treatment in early Parkinson's disease</title><genre><json:string>article</json:string></genre><host><volume>64</volume><publisherId><json:string>ANA</json:string></publisherId><pages><total>9</total><last>S55</last><first>S47</first></pages><issn><json:string>0364-5134</json:string></issn><issue>S2</issue><subject><json:item><value>Clinical Issues</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8249</json:string></eissn><title>Annals of Neurology</title><doi><json:string>10.1002/(ISSN)1531-8249</json:string></doi></host><publicationDate>2008</publicationDate><copyrightDate>2008</copyrightDate><doi><json:string>10.1002/ana.21460</json:string></doi><id>643A71F9A8ABD53E53147889FF258AAAB8E2EC74</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/643A71F9A8ABD53E53147889FF258AAAB8E2EC74/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/643A71F9A8ABD53E53147889FF258AAAB8E2EC74/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/643A71F9A8ABD53E53147889FF258AAAB8E2EC74/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Drug selection and timing of initiation of treatment in early Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2008</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: This article is part of a supplement sponsored by Boehringer Ingelheim (BI). A.H.V.S. has received honoraria as a consultant for BI, GlaxoSmithKline, Teva, Lundbeck, Novartis, Orion, and Solvay. C.W.O. has served as a consultant to BI, Novartis, Teva, Merck Serono, and Ceregene.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Drug selection and timing of initiation of treatment in early Parkinson's disease</title><author><persName><forename type="first">Anthony H. V.</forename><surname>Schapira</surname></persName><roleName type="degree">MD, DSc, FRCP, FMedSci</roleName><note type="correspondence"><p>Correspondence: University Department of Clinical Neurosciences, Institute of Neurology, Rowland Hill Street, London, NW3 2PF, United Kingdom</p></note><affiliation>University Department of Clinical Neuroscience, Institute of Neurology, London, United Kingdom</affiliation></author><author><persName><forename type="first">C. Warren</forename><surname>Olanow</surname></persName><roleName type="degree">MD, FRCPC</roleName><affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, NY</affiliation></author></analytic><monogr><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="pISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><idno type="DOI">10.1002/(ISSN)1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-12"></date><biblScope unit="volume">64</biblScope><biblScope unit="issue">S2</biblScope><biblScope unit="supplement">2</biblScope><biblScope unit="page" from="S47">S47</biblScope><biblScope unit="page" to="S55">S55</biblScope></imprint></monogr><idno type="istex">643A71F9A8ABD53E53147889FF258AAAB8E2EC74</idno><idno type="DOI">10.1002/ana.21460</idno><idno type="ArticleID">ANA21460</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2008</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>There is increasing evidence to challenge the traditional view that the initiation of drug treatment in Parkinson's disease (PD) should be delayed until the patient has significant disability such as to affect work or social function. Firstly, to delay treatment sentences the patient to protracted impairment of quality of life that could be improved by therapy. Secondly, there is evidence to support the notion that earlier rather than later initiation of treatment leads to better long term motor benefit. The selection of which drug to begin must be tailored to the patient's individual characteristics and circumstances. Monoamine oxidase B inhibitors result in a mild improvement in motor function compared to dopamine agonists or levodopa. They are well tolerated, easy to use once a day drugs and there is evidence that early use of Rasagiline improves motor outcome. Dopamine agonists lead to a substantial improvement in motor function and are, or will shortly be, available as once a day drugs. They are generally well tolerated but can be associated with exacerbating confusion or hallucinations and with behavioral changes. Levodopa is the most potent of the dopaminergic drugs. It is routinely combined with a dopa decarboxylase inhibitor and can also be used with a catecholo‐o‐methyl transferase inhibitor for enhanced absorption. The most important limiting factor for the use of levodopa is the emergence of motor complications. These are related to a number of factors including the dose of levodopa and the duration of its use. Ann Neurol 2008;64 (suppl):S47–S55</p></abstract><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Clinical Issues</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-03-29">Received</change><change when="2008-06-13">Registration</change><change when="2008-12">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/643A71F9A8ABD53E53147889FF258AAAB8E2EC74/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8249</doi><issn type="print">0364-5134</issn><issn type="electronic">1531-8249</issn><idGroup><id type="product" value="ANA"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="ANNALS OF NEUROLOGY">Annals of Neurology</title><title type="subtitle">Official Journal of the American Neurological Association and the Child Neurology Society</title><title type="short">Ann Neurol.</title></titleGroup></publicationMeta><publicationMeta level="part" position="250"><doi origin="wiley" registered="yes">10.1002/ana.v64:2+</doi><titleGroup><title type="supplementTitle">Unresolved Issues in Parkinson's Disease</title></titleGroup><numberingGroup><numbering type="journalVolume" number="64">64</numbering><numbering type="journalIssue">S2</numbering><numbering type="supplement" number="2">2</numbering></numberingGroup><coverDate startDate="2008-12">December 2008</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="50" status="forIssue"><doi origin="wiley" registered="yes">10.1002/ana.21460</doi><idGroup><id type="unit" value="ANA21460"></id></idGroup><countGroup><count type="pageTotal" number="9"></count></countGroup><titleGroup><title type="articleCategory">Clinical Issues</title><title type="tocHeading1">Clinical Issues</title></titleGroup><copyright ownership="thirdParty">Copyright © 2008 American Neurological Association</copyright><eventGroup><event type="manuscriptReceived" date="2008-03-29"></event><event type="manuscriptRevised" date="2008-06-06"></event><event type="manuscriptAccepted" date="2008-06-13"></event><event type="firstOnline" date="2009-01-06"></event><event type="publishedOnlineFinalForm" date="2009-01-06"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.1 mode:FullText source:FullText result:FullText" date="2010-02-23"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-03"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst">S47</numbering><numbering type="pageLast">S55</numbering></numberingGroup><correspondenceTo>University Department of Clinical Neurosciences, Institute of Neurology, Rowland Hill Street, London, NW3 2PF, United Kingdom</correspondenceTo><objectNameGroup><objectName elementName="figure">Illustration</objectName></objectNameGroup><linkGroup><link type="toTypesetVersion" href="file:ANA.ANA21460.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="91"></count><count type="wordTotal" number="7759"></count></countGroup><titleGroup><title type="main" xml:lang="en">Drug selection and timing of initiation of treatment in early Parkinson's disease<link href="#fn1"></link></title><title type="short" xml:lang="en">Treatment Initiation in PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Anthony H. V.</givenNames><familyName>Schapira</familyName><degrees>MD, DSc, FRCP, FMedSci</degrees></personName><contactDetails><email>a.schapira@medsch.ucl.ac.uk</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>C. Warren</givenNames><familyName>Olanow</familyName><degrees>MD, FRCPC</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="GB" type="organization"><unparsedAffiliation>University Department of Clinical Neuroscience, Institute of Neurology, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Mount Sinai School of Medicine, New York, NY</unparsedAffiliation></affiliation></affiliationGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>There is increasing evidence to challenge the traditional view that the initiation of drug treatment in Parkinson's disease (PD) should be delayed until the patient has significant disability such as to affect work or social function. Firstly, to delay treatment sentences the patient to protracted impairment of quality of life that could be improved by therapy. Secondly, there is evidence to support the notion that earlier rather than later initiation of treatment leads to better long term motor benefit. The selection of which drug to begin must be tailored to the patient's individual characteristics and circumstances. Monoamine oxidase B inhibitors result in a mild improvement in motor function compared to dopamine agonists or levodopa. They are well tolerated, easy to use once a day drugs and there is evidence that early use of Rasagiline improves motor outcome. Dopamine agonists lead to a substantial improvement in motor function and are, or will shortly be, available as once a day drugs. They are generally well tolerated but can be associated with exacerbating confusion or hallucinations and with behavioral changes. Levodopa is the most potent of the dopaminergic drugs. It is routinely combined with a dopa decarboxylase inhibitor and can also be used with a catecholo‐o‐methyl transferase inhibitor for enhanced absorption. The most important limiting factor for the use of levodopa is the emergence of motor complications. These are related to a number of factors including the dose of levodopa and the duration of its use. Ann Neurol 2008;64 (suppl):S47–S55</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: This article is part of a supplement sponsored by Boehringer Ingelheim (BI). A.H.V.S. has received honoraria as a consultant for BI, GlaxoSmithKline, Teva, Lundbeck, Novartis, Orion, and Solvay. C.W.O. has served as a consultant to BI, Novartis, Teva, Merck Serono, and Ceregene.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Drug selection and timing of initiation of treatment in early Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Treatment Initiation in PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Drug selection and timing of initiation of treatment in early Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Anthony H. V.</namePart><namePart type="family">Schapira</namePart><namePart type="termsOfAddress">MD, DSc, FRCP, FMedSci</namePart><affiliation>University Department of Clinical Neuroscience, Institute of Neurology, London, United Kingdom</affiliation><description>Correspondence: University Department of Clinical Neurosciences, Institute of Neurology, Rowland Hill Street, London, NW3 2PF, United Kingdom</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C. Warren</namePart><namePart type="family">Olanow</namePart><namePart type="termsOfAddress">MD, FRCPC</namePart><affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, NY</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2008-12</dateIssued><dateCaptured encoding="w3cdtf">2008-03-29</dateCaptured><dateValid encoding="w3cdtf">2008-06-13</dateValid><copyrightDate encoding="w3cdtf">2008</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="references">91</extent><extent unit="words">7759</extent></physicalDescription><abstract lang="en">There is increasing evidence to challenge the traditional view that the initiation of drug treatment in Parkinson's disease (PD) should be delayed until the patient has significant disability such as to affect work or social function. Firstly, to delay treatment sentences the patient to protracted impairment of quality of life that could be improved by therapy. Secondly, there is evidence to support the notion that earlier rather than later initiation of treatment leads to better long term motor benefit. The selection of which drug to begin must be tailored to the patient's individual characteristics and circumstances. Monoamine oxidase B inhibitors result in a mild improvement in motor function compared to dopamine agonists or levodopa. They are well tolerated, easy to use once a day drugs and there is evidence that early use of Rasagiline improves motor outcome. Dopamine agonists lead to a substantial improvement in motor function and are, or will shortly be, available as once a day drugs. They are generally well tolerated but can be associated with exacerbating confusion or hallucinations and with behavioral changes. Levodopa is the most potent of the dopaminergic drugs. It is routinely combined with a dopa decarboxylase inhibitor and can also be used with a catecholo‐o‐methyl transferase inhibitor for enhanced absorption. The most important limiting factor for the use of levodopa is the emergence of motor complications. These are related to a number of factors including the dose of levodopa and the duration of its use. Ann Neurol 2008;64 (suppl):S47–S55</abstract><note type="content">*Potential conflict of interest: This article is part of a supplement sponsored by Boehringer Ingelheim (BI). A.H.V.S. has received honoraria as a consultant for BI, GlaxoSmithKline, Teva, Lundbeck, Novartis, Orion, and Solvay. C.W.O. has served as a consultant to BI, Novartis, Teva, Merck Serono, and Ceregene.</note><relatedItem type="host"><titleInfo><title>Annals of Neurology</title><subTitle>Official Journal of the American Neurological Association and the Child Neurology Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Ann Neurol.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Clinical Issues</topic></subject><identifier type="ISSN">0364-5134</identifier><identifier type="eISSN">1531-8249</identifier><identifier type="DOI">10.1002/(ISSN)1531-8249</identifier><identifier type="PublisherID">ANA</identifier><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><detail type="issue"><caption>no.</caption><number>S2</number></detail><detail type="supplement"><caption>Suppl. no.</caption><number>2</number></detail><extent unit="pages"><start>S47</start><end>S55</end><total>9</total></extent></part></relatedItem><identifier type="istex">643A71F9A8ABD53E53147889FF258AAAB8E2EC74</identifier><identifier type="DOI">10.1002/ana.21460</identifier><identifier type="ArticleID">ANA21460</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2008 American Neurological Association</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000205 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000205 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:643A71F9A8ABD53E53147889FF258AAAB8E2EC74
|texte= Drug selection and timing of initiation of treatment in early Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |